A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer

Creative Commons License

Senan S., Cardenal F., Vansteenkiste J., Stigt J., Akyol F., De Neve W., ...More

ANNALS OF ONCOLOGY, vol.22, no.3, pp.553-558, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 3
  • Publication Date: 2011
  • Doi Number: 10.1093/annonc/mdq388
  • Journal Name: ANNALS OF ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.553-558
  • Hacettepe University Affiliated: Yes


Background: In stage III non-small-cell lung cancer (NSCLC), the role of systemic chemotherapy preceding or following concurrent chemo-radiotherapy (CT-RT) is unclear. We carried out a randomized phase II study to study the toxicity involved-field CT-RT with either induction or consolidation cisplatin-docetaxel (Taxotere).